|
1
|
van Spronsen DJ, Mulders PF and De Mulder
PH: Novel treatments for metastatic renal cell carcinoma. Crit Rev
Oncol Hematol. 55:177–191. 2005.
|
|
2
|
Jemal A, Siegel R, Xu J and Ward E: Cancer
statistics, 2010. CA Cancer J Clin. 60:277–300. 2010.
|
|
3
|
Cohen HT and McGovern FJ: Renal-cell
carcinoma. N Engl J Med. 353:2477–2490. 2005.
|
|
4
|
Motzer RJ, Bander NH and Nanus DM:
Renal-cell carcinoma. N Engl J Med. 335:865–875. 1996.
|
|
5
|
Kerbel RS: Tumor angiogenesis. N Engl J
Med. 358:2039–2049. 2008.
|
|
6
|
Jain RK, Duda DG, Clark JW and Loeffler
JS: Lessons from phase III clinical trials on anti-VEGF therapy for
cancer. Nat Clin Pract Oncol. 3:24–40. 2006.
|
|
7
|
Lai EC: Notch signaling: control of cell
communication and cell fate. Development. 131:965–973. 2004.
|
|
8
|
Kopan R and Ilagan MX: The canonical notch
signaling pathway: unfolding the activation mechanism. Cell.
137:216–233. 2009.
|
|
9
|
Noguera-Troise I, Daly C, Papadopoulos NJ,
et al: Blockade of Dll4 inhibits tumour growth by promoting
non-productive angiogenesis. Nature. 444:1032–1037. 2006.
|
|
10
|
Hellström M, Phng LK, Hofmann JJ, et al:
Dll4 signalling through Notch1 regulates formation of tip cells
during angiogenesis. Nature. 445:776–780. 2007.
|
|
11
|
Lobov IB, Renard RA, Papadopoulos N, et
al: Delta-like ligand 4 (Dll4) is induced by VEGF as a negative
regulator of angiogenic sprouting. Proc Natl Acad Sci USA.
104:3219–3224. 2007.
|
|
12
|
Hoey T, Yen WC, Axelrod F, et al: DLL4
blockade inhibits tumor growth and reduces tumor-initiating cell
frequency. Cell Stem Cell. 5:168–177. 2009.
|
|
13
|
Mailhos C, Modlich U, Lewis J, Harris A,
Bicknell R and Ish-Horowicz D: Delta4, an endothelial specific
notch ligand expressed at sites of physiological and tumor
angiogenesis. Differentiation. 69:135–144. 2001.
|
|
14
|
Patel NS, Dobbie MS, Rochester M, et al:
Up-regulation of endothelial delta-like 4 expression correlates
with vessel maturation in bladder cancer. Clin Cancer Res.
12:4836–4844. 2006.
|
|
15
|
Jubb AM, Soilleux EJ, Turley H, et al:
Expression of vascular notch ligand delta-like 4 and inflammatory
markers in breast cancer. Am J Pathol. 176:2019–2028. 2010.
|
|
16
|
Jubb AM, Turley H, Moeller HC, et al:
Expression of delta-like ligand 4 (Dll4) and markers of hypoxia in
colon cancer. Br J Cancer. 101:1749–1757. 2009.
|
|
17
|
Patel NS, Li JL, Generali D, Poulsom R,
Cranston DW and Harris AL: Up-regulation of delta-like 4 ligand in
human tumor vasculature and the role of basal expression in
endothelial cell function. Cancer Res. 65:8690–8697. 2005.
|
|
18
|
Donnem T, Andersen S, Al-Shibli K, Al-Saad
S, Busund LT and Bremnes RM: Prognostic impact of Notch ligands and
receptors in nonsmall cell lung cancer: coexpression of Notch-1 and
vascular endothelial growth factor-A predicts poor survival.
Cancer. 116:5676–5685. 2010.
|
|
19
|
Chen HT, Cai QC, Zheng JM, et al: High
Expression of Delta-Like Ligand 4 Predicts Poor Prognosis After
Curative Resection for Pancreatic Cancer. Ann Surg Oncol. 19(Suppl
3): S464–S474. 2012.
|
|
20
|
Martínez-Salamanca JI, Huang WC, Millán I,
et al: International Renal Cell Carcinoma-Venous Thrombus
Consortium: Prognostic impact of the 2009 UICC/AJCC TNM staging
system for renal cell carcinoma with venous extension. Eur Urol.
59:120–127. 2011.
|
|
21
|
Fuhrman SA, Lasky LC and Limas C:
Prognostic significance of morphologic parameters in renal cell
carcinoma. Am J Surg Pathol. 6:655–663. 1982.
|
|
22
|
Linehan WM and Zbar B: Focus on kidney
cancer. Cancer Cell. 6:223–228. 2004.
|
|
23
|
Suchting S, Freitas C, le Noble F, et al:
The Notch ligand Delta-like 4 negatively regulates endothelial tip
cell formation and vessel branching. Proc Natl Acad Sci USA.
104:3225–3230. 2007.
|
|
24
|
Scehnet JS, Jiang W, Kumar SR, et al:
Inhibition of Dll4-mediated signaling induces proliferation of
immature vessels and results in poor tissue perfusion. Blood.
109:4753–4760. 2007.
|
|
25
|
Zhang JX, Cai MB, Wang XP, et al: Elevated
DLL4 expression is correlated with VEGF and predicts poor prognosis
of nasopharyngeal carcinoma. Med Oncol. 30:3902013.
|
|
26
|
Ridgway J, Zhang G, Wu Y, et al:
Inhibition of Dll4 signalling inhibits tumour growth by
deregulating angiogenesis. Nature. 444:1083–1087. 2006.
|
|
27
|
Thurston G, Noguera-Troise I and
Yancopoulos GD: The Delta paradox: DLL4 blockade leads to more
tumour vessels but less tumour growth. Nat Rev Cancer. 7:327–331.
2007.
|
|
28
|
Escudier B, Eisen T, Stadler WM, et al:
TARGET study group: Sorafenib in advanced clear-cell renal-cell
carcinoma. N Engl J Med. 356:125–134. 2007.
|
|
29
|
Motzer RJ, Hutson TE, Tomczak P, et al:
Sunitinib versus interferon alfa in metastatic renal-cell
carcinoma. N Engl J Med. 356:115–124. 2007.
|
|
30
|
Yang JC, Haworth L, Sherry RM, et al: A
randomized trial of bevacizumab, an anti-vascular endothelial
growth factor antibody, for metastatic renal cancer. N Engl J Med.
349:427–434. 2003.
|
|
31
|
Ferrara N, Hillan KJ, Gerber H-P and
Novotny W: Discovery and development of bevacizumab, an anti-VEGF
antibody for treating cancer. Nat Rev Drug Discov. 3:391–400.
2004.
|
|
32
|
Ebos JM, Lee CR and Kerbel RS: Tumor and
host-mediated pathways of resistance and disease progression in
response to antiangiogenic therapy. Clin Cancer Res. 15:5020–5025.
2009.
|
|
33
|
Duda DG, Batchelor TT, Willett CG and Jain
RK: VEGF-targeted cancer therapy strategies: current progress,
hurdles and future prospects. Trends Mol Med. 13:223–230. 2007.
|
|
34
|
Kuhnert F, Kirshner JR and Thurston G:
Dll4-Notch signaling as a therapeutic target in tumor angiogenesis.
Vasc Cell. 3:202011.
|
